Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds.
Alzheimer's disease
Cholinesterase
Dual inhibitors
Heterocyclic scaffolds.
Monoamine oxidase
Parkinson’s disease
Journal
Current topics in medicinal chemistry
ISSN: 1873-4294
Titre abrégé: Curr Top Med Chem
Pays: United Arab Emirates
ID NLM: 101119673
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
06
2021
revised:
28
07
2021
accepted:
05
08
2021
pubmed:
4
9
2021
medline:
22
1
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
For the last two decades, there has been research interest on the design of molecules possessing dual inhibitory potential on cholinesterase and monoamine oxidase enzymes, particularly for the treatment of two major neurodegenerative diseases, Alzheimer's Disease (AD) and Parkinson's disease (PD). Many compounds have been synthesized for this purpose, and some of them have been shown to display activities comparable or superior to the activities of current drugs used for the treatment of AD and PD. Within the concept of this review study, we have aimed to present the current drugs used for the treatment of AD and PD, their mechanism of action, the discussion behind the theory of designing dual inhibitor agents, and the presentation of the most active compounds with diverse heterocyclic scaffolds displayed in research studies published in the recent period.
Identifiants
pubmed: 34477521
pii: CTMC-EPUB-117629
doi: 10.2174/1568026621666210902121148
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Monoamine Oxidase Inhibitors
0
Dual Oxidases
EC 1.11.1.-
Monoamine Oxidase
EC 1.4.3.4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2752-2765Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.